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Abstract
Deletions in the 2p16.3 region that includes the neurexin (NRXN1) gene are
associated with intellectual disability and various psychiatric disorders, in par-
ticular, autism and schizophrenia. We present three unrelated patients, two
adults and one child, in whom we identified an intragenic 2p16.3 deletion
within the NRXN1 gene using an oligonucleotide comparative genomic hybrid-
ization array. The three patients presented dual diagnosis that consisted of mild
intellectual disability and autism and bipolar disorder. Also, they all shared a
dysmorphic phenotype characterized by a long face, deep set eyes, and promi-
nent premaxilla. Genetic analysis of family members showed two inherited dele-
tions. A comprehensive neuropsychological examination of the 2p16.3 deletion
carriers revealed the same phenotype, characterized by anxiety disorder, border-
line intelligence, and dysexecutive syndrome. The cognitive pattern of dysexecu-
tive syndrome with poor working memory and reduced attention switching,
mental flexibility, and verbal fluency was the same than those of the adult pro-
bands. We suggest that in addition to intellectual disability and psychiatric dis-
ease, NRXN1 deletion is a risk factor for a characteristic cognitive and
dysmorphic profile. The new cognitive phenotype found in the 2p16.3 deletion
carriers suggests that 2p16.3 deletions might have a wide variable expressivity
instead of incomplete penetrance.
Introduction
Copy number variants (CNVs) are 1 kb or larger DNA
segments that are deleted or duplicated when compared to
a reference genome (Redon et al. 2006). They are found in
all humans as polymorphisms. CNVs are currently emerg-
ing as an important genomic cause of disease (Rujescu
et al. 2009) through disruption of genes and alteration of
gene dosage. As a consequence, CNVs influence gene
expression, phenotypic variation, and confer risk of com-
plex disease traits (Redon et al. 2006). Application of array
comparative genomic hybridization (aCGH) facilitates
genotyping of large cohorts and the determination of new
genotype–phenotype correlations. This technique has
become a valuable tool for the study of mental health
associated with intellectual disability (ID). Indeed, whereas
the karyotype only identifies abnormalities in 5% of
people with ID, aCGH increases the diagnostic yield to
11–15% (Miller et al. 2010) and up to 5–10% in autistic
patients (Miller et al. 2010; Nava et al. 2014).
Clinical geneticists need to discriminate pathogenic
from benign CNVs. Large studies have classified CNVs
as benign variant, causative variant, or risk factor based
on genetic content, function of genes included in the
aberration, and CNVs inheritance pattern (Miller et al.
2010; Cooper et al. 2011; Vermeesch et al. 2012). In
most studies de novo rearrangements are usually
considered pathogenic, whereas inherited rearrangements
from an unaffected parent are considered benign. How-
ever, some CNVs predispose to a specific phenotype
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with incomplete penetrance and inherited
abnormalities can be significant even when phenotypes
are highly discrepant between family members (Baker
et al. 2012).
Genes that influence synaptic activity may contribute
to different psychiatric and neurodevelopmental condi-
tions. In a population without ID, CNVs increase sus-
ceptibility to schizophrenia and bipolar disease. In these
cases, an enrichment of large (>100 kb) CNVs is
observed (Malhotra and Sebat 2012). Moreover, CNVs
are strongly correlated with the etiology of dual
diagnosis such as ID and psychiatric disorders and/or
challenging behavior. Although the prevalence of
psychiatric disorders in adults with ID is higher (Deb
et al. 2001; Cooper et al. 2007; Siegel and Smith 2010),
the epidemiology of psychiatric disorders in the context
of ID remains poorly understood because of the diffi-
culties associated with diagnosis.
The neurexines (NRXN) are a group of highly poly-
morphic cell surface receptors that influence synaptic
activity and contribute to ID and psychiatric disorders.
NRXN1 is a large gene with two independent promot-
ers that lead the generation of longer NRXN1-a and
shorter NRXN1-b extracellular variants and multiple
alternative splice sites resulting in more than 3000 iso-
forms (Runkel et al. 2013). Different NRXN1 transcripts
interact with extracellular binding partners such as neu-
roligins (NLGN), leucine-rich repeat transmembrane
neuronal protein 2, cerebellin, and dystroglycan (Missler
et al. 2012). NRXN1 binds to NLGN to form a cal-
cium-dependent neurexin/neuroligin complex in the
synapses of the central nervous system. This complex is
crucial for an efficient neurotransmission and is
involved in the formation of synaptic contacts (Reissner
et al. 2008). The NRXN1 gene is located in 2p16.3 and
contains 24 exons that span 1.1 Mb with very large in-
trons. NRXN1 is one of the largest known human
genes and it can be affected by gene disruption includ-
ing missense changes, translocations, whole gene dele-
tion, and intragenic copy number alterations with
relative frequency (Ching et al. 2010). There is evidence
that CNVs involving NRXN1 are associated with cogni-
tive ability, language development disorders, autism,
and several psychiatric disorders, in particular, schizo-
phrenia (0.47% in affected cases in contrast to 0.15%
in the control population) (Bucan et al. 2009; Gratacos
et al. 2009; Guilmatre et al. 2009; Need et al. 2009; Ru-
jescu et al. 2009; Ching et al. 2010; Ikeda et al. 2010;
Magri et al. 2010; Dabell et al. 2013). Results of a
mouse model study suggest that deletion of the Nrxn1
gene in mice leads to anxiety, aggression, alterations in
social behavior, locomotor activity, and normal home
cage behavior (Grayton et al. 2013). Most described
cases have a de novo NRXN1 deletion, but some have
been inherited from an unaffected parent suggesting an
incomplete penetrance.
A large series of patients with exonic deletions in
2p16.3 region and NRXN1 mutations have been reported
recently (Bena et al. 2013). The authors described devel-
opmental, neuropsychiatric, and cognitive phenotypes
associated with NRXN1 haploinsufficiency, but they did
not include neuropsychological and psychiatric profiles
for NRXN1 deletion carriers. In this article, we describe
three unrelated patients with a 2p16.3 deletion disrupting
the NRXN1 gene that present common dysmorphic, cog-
nitive, psychiatric, and behavioral features. Moreover,
family members who carry the deletion have been neuro-
psychological assessed.
Methods
Patients were seen at the Service for Mental Health and
Intellectual Disability at the Parc Hospitalari Martı i Julia
(Girona, Catalunya, Spain) and referred to the Clinical
Genetics Department at the Corporacio Sanitaria Parc
Taulı (Sabadell, Catalunya, Spain) for clinical assessment.
Informed consent was obtained from the patients and/or
their carers.
Clinical data
Registered variables were clinical characteristics and personal
and family history. Different tests based on the intelligence
level of the participants were used to evaluate psychiatric,
cognitive, and behavioral disorders (see Table 1).
The psychiatric diagnostic was classified according to
ICD-10-ID (International Classification of Diseases –
Intellectual Disabilities) and DC-LD (Diagnostic Criteria
– Learning Disabilities) for the adult probands with ID
and according to DSM-V for family members.
Genetic analyses
DNA from probands and their family members was
extracted from peripheral blood lymphocytes using the
Gentra Puregene DNA reagent (Qiagen, Valencia, CA).
Karyotype (800-G bands) and aCGH using the Agilent
platform 400K (Agilent Technologies, Santa Clara, CA)
were performed in all patient samples. Microarray pro-
cessing was carried out according to manufacturer’s
specifications. For analyses of microarray data, Agilent
Workbench 5.0 and Cytogenomics software (Agilent
Technologies) and Nexus 6.1 (BioDiscovery, Hawthorne,
CA) were used. Common CNVs (prevalence >1% in
the general population) were excluded and validation of
rare CNVs was performed by customized MLPA,
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designing specific probes according to protocols and
guidelines from MRC-Holland (Amsterdam, the Nether-
lands) and the ProSeek web server created by Pantano
et al. (2008). Once validated, family samples were also
analyzed and CNVs were finally classified in three cate-
gories: pathogenic variants, benign variants, and variants
of uncertain clinical significance (VOUS) (Miller et al.
2010; Vermeesch et al. 2012).
All genomic coordinates are in agreement with the
UCSC Genome Browser for March 2006 (UCSC hg18,
NCBI build 36).
Results
Molecular results
The three cases presented a partial deletion in the 2p16.3
region affecting the NRXN1 gene. Exons were removed
from 5 to 18 in cases 1 and 2 and from 1 to 5 in case 3
(Fig. 1). In all cases, other rare CNVs were found
(Table 2). The deletion was maternally inherited in cases
2 and 3. Also, two aunts of case 3 were carriers of the
deletion.
Table 1. Summary of different tests used to evaluate psychiatric, cognitive, and behavioral disorders according to the level of intelligence and the
age.
Cases 1 and 2: adults patients Case 3: child Family members
Psychopathological evaluation PASS-ADD TCI-R
Compulsive behavior checklist PAI 4
Y-BOCS
Cognitive evaluation K-BIT WISC-IV K-BIT
FCRO Bayley II FCRO
Color Trail Test 1 and 2 Reynell Color Trails Test 1 and 2
PIEN-ID WMS-III
BRIEF BNT
ADOS Semantic verbal fluency
Tower of London FAS
Stroop
BADS
RAVLT
Tower of London
Behavioral evaluation ABC scale
ABS-RC:2
PASS-ADD, Psychiatric Assessment for Adults with Developmental Disabilities; Y-BOCS, Yale-Brown Obsessive–Compulsive Scale; TCI-R, Tempera-
ment and Character Inventory–Revised; PAI, Personality Assessment Inventory; K-BIT, Kaufman Brief Intelligence Test; FCRO, Rey–Osterriech Com-
plex Figure; PIEN-ID, Neuropsychological Integrated Program for people with Intellectual Disabilities; BRIEF, Behavioral Rating Inventory of
Executive Function; ADOS, Autism Diagnostic Observation Schedule; WISC-IV, Wechsler Intelligence Scale for Children; WMS-III, Digits; BNT, Bos-
ton Naming Test; FAS, verbal fluency; BADS, Behavioral Assessment of Dysexecutive Syndrome; RAVLT, Rey Auditive Verbal Learning Test; ABC
Scale, Aberrant Behavior Checklist; ABS-RC, Adaptive Behavior Scale – Residential and Community – Second edition.
Figure 1. Neurexin deletion identified in case 1 (blue bar), case 2 (red bar), and case 3 (green bar). At the top of the figure is an ideogram of
chromosome band 2p16.3 with genomic coordinates corresponding to the hg18 build of the human genome. Two major NRXN1 isoforms are
shown in black with vertical bars representing the localization of exonic regions. 2p16.3 deletion in cases 1 and 3 affects a isoform while 2p16.3
deletion in case 2 affect both a and b isoforms.
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Clinical results
Case 1
The proband (Fig. 2A, III.2) was a 21-year-old female,
the only child of nonconsanguineous parents. Pregnancy
was uneventful and she was born full-term with a weight
of 3640 g and length of 52 cm. No congenital abnormali-
ties or feeding difficulties were observed and she started
to walk at 14 months of age. The patient had febrile sei-
zures until she was 2 years old and childhood absence
epilepsy from 5 until 7 years of age. She presented diffi-
culties in language acquisition and at the age of 12 she
went to a special education school. She had a normal
growth and puberty and age at menarche was 14 years.
During the clinical assessment the patient presented a
weight and height in the 97th centiles, an occipitofrontal
circumference (OFC) of 56.5 cm (+1 SD) and good gen-
eral health. Facial dysmorphism included long face, deep
set eyes, hypotelorism, low set ears, prominent premaxilla,
a high, narrow palate, and tooth malposition (Fig. 2B and
C, Table 3). She also had dorsal kyphosis and long hands
with slender, flexible fingers.
Psychiatric, cognitive, and behavioral profile
The patient had a diagnosis of bipolar disorder with a
behavioral profile characterized by inappropriate reactions
to frustration, which translated in refusal to follow direc-
tions, requests, or orders. Her performance on the autism
diagnostic observation schedule (ADOS) was not indica-
tive of autism spectrum disorder (ASD) or autism. Neu-
ropsychological tests showed a mild ID with an
intelligence quotient (IQ) of 65. The cognitive profile
showed a dysexecutive syndrome with particularly poor
behavioral control, low tolerance to frustration, and diffi-
culty in acquiring new information, both verbal and
visual (Fig. 3). Language scores were within average.
The parents did not have the 2p16.3 deletion and their
psychiatric and cognitive results were within normal
range.
Case 2
The patient (Fig. 2D, II.1) was a 20-year-old male with a
history of ID. His mother and brother had a history of
behavioral disorders. Pregnancy was uneventful; delivery
was full-term and dystocic. The patient had a birthweight
of 2790 g and OFC of 33.5 cm. No congenital abnormali-
ties or feeding difficulties were observed at birth. He pre-
sented a normal growth pattern throughout childhood
and puberty. At the time of assessment he had a weight
of 65.5 kg (25th centile), height of 167 cm (3–10th cen-
tile), and OFC of 54 cm (1.5 SD). Facial dysmorphism
included long face, deep set eyes, hypotelorism, low set
ears, prominent premaxilla, and high palate (Fig. 2E and
F, Table 3). He presented dorsal kyphosis and finger
rigidity.
Psychiatric, cognitive, and behavioral profile
The proband presented a nonspecified psychotic disorder
with hypochondriac delusions. His behavior included
explosive temper tantrums, violence, and property
destruction with a diagnosis of verbal and physically
aggressive destructive behavior. Within his diagnosis of
atypical autism, the patient also presented obsessive–com-
pulsive behavior. His performance on the ADOS placed
him within the ASD range. Neuropsychological tests
showed a mild ID with an IQ of 62 and a complex cogni-
tive profile, which included concretism and severe impair-
ment of executive functioning, mainly in relation to
working memory, difficulty in classifying information cor-
rectly, and deficit of abstract reasoning (Fig. 4).
The proband’s mother, a 53-year-old housewife, was a
carrier of the 2p16.3 deletion. She was schooled just for
Table 2. Summary of genotyping results.
CNVs BP (hg18) Length (kb) Genes Inheritance
Case 1 Deletion 2p16.31 50,514,386–50,932,097 417 NRXN1 De novo
Deletion 2q21.3 135,549,169–135,581,884 327 RAB3GAP1 Maternal
Duplication 5q12.1 59,751,669–59,807,274 56 PDE4D Paternal
Case 2 Deletion 2p16.31 50,364,106–50,990,775 627 NRXN1 Maternal
Deletion 15q22.3 63,116,991–63,149,937 33 OSTb RASL12 Maternal
Case 3 Deletion 2p16.31 50,894,085–51,410,728 516 NRXN1 Maternal
Deletion 6q22.31 121,325,237–121,479,133 154 c6orf170 NA
Duplication 8q13.2 70,441,952–70,587,123 145 SUF1 NA
Duplication 10q25.3 117,713,715–118,044,856 331 GFRA1 NA
BP, break points; NA, not analyzed.
1Common 2p16.3 deletion in the three cases.
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3 years and presented a cognitive function and perfor-
mance which correlated with an IQ of 69 (borderline).
Her behavior was characterized by jealousy, poor self-con-
trol, suspicion, mood fluctuations, and emotional insta-
bility. She presented impulsive and anxiety traits. The
neuropsychological tests revealed poor working memory
and a dysexecutive pattern.
The proband’s father was 51 years old. He presented a
cognitive function and performance which correlated with
an IQ of 97 (normal intelligence). No personality or psy-
chiatric disorders were diagnosed.
The proband’s brother was not a carrier of the 2p16.3
deletion. He was a 21-year-old man with an IQ of 76
(borderline) that performed poorly at school. He had
never received psychiatric or psychological treatment.
Case 3
The proband (Fig. 2G, III.1) was a 11-year-old boy, the
only child of nonconsanguineous parents. During the
pregnancy the mother suffered hyperemesis gravidarum, a
surgical intervention for a sacral cyst and retroplacental
hematoma. The proband was born full-term with a
birthweight of 2800 g and length of 50 cm. No congenital
abnormalities were observed on examination at birth, but
he had breastfeeding and artificial feeding difficulties and
frequent vomiting. At the age of 3, he was not able to
chew, had not acquired any language, and presented
severe sleep disturbances, together with maladaptive and
self-harming behavior. At the age of 9, he was diagnosed
of attention deficit hyperactivity disorder and cognitive
delay. The patient was in a mainstream school where he
followed a special program. He still presented many fears,
sleep disturbances, and looked very anxious. His height,
weight, and OFC had consistently been in the third cen-
tile. He also presented facial dysmorphism with a mildly
long face, deep set eyes, prominent premaxilla, and long
philtrum (Fig. 2H–J, Table 3).
Psychiatric, cognitive, and behavioral profile
The patient presented autistic traits, with hyperactivity
and challenging behavior as his most salient psychopatho-
logical features. He had a mild ID with an IQ of 53 and a
neuropsychological profile characterized by language
impairment (both expression and comprehension), poor
working memory, and attention. Visual reasoning perfor-
mance was good.
The proband’s mother was a 36-year-old woman, car-
rier of the 2p16.3 deletion, and the fourth of five chil-
dren. She had a borderline intelligence (IQ = 75).
Cognitive impairment had already been detected at pri-
mary school, where she performed poorly. The psychiatric
evaluation found a generalized anxiety disorder with
Figure 2. Pedigrees and photographs. (A)
Case 1 pedigree; (B, C) case 1 at the age of
21; (D) case 2 pedigree; (E, F) case 2 at the
age of 20; (G) case 3 pedigree; (H, I) case 3 at
the age of three; (J) case 3 at the age of 11.
Arrows indicate proband.
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significant higher scores on anxiety scales (76) and anxi-
ety-related disorders (71). A significant high score on the
scale of lack of social support was obtained (74), reflect-
ing a perception of little support. The Temperament and
Character Inventory–Revised (TCI-R) results showed the
same personality pattern. She had not received psychiatric
or psychological support. The cognitive profile showed a
dysexecutive syndrome characterized by difficulties in
working memory, attention switching, mental flexibility,
and verbal fluency.
The proband’s father, a 42-year-old man, had an IQ of
100. He required treatment for obsessive–compulsive dis-
order. The cognitive evaluation of the proband’s father
showed a reduced verbal memory. Executive functions
and visual abilities were not impaired.
Two maternal aunts (II.1 and II.6) had the 2p16.3 dele-
tion (Fig. 2G). The first carrier (II.1) had an average
intelligence (IQ = 91). The scores on the Personality
Assessment Inventory (PAI) were within normal range
and did not highlight any clinical scale or subscale. A ten-
dency to respond aggressively and angrily to small provo-
cations was observed by a slight elevation in aggression
subscales. The TCI-R showed a histrionic personality dis-
order. Her cognitive profile presented poor mental flexi-
bility and inhibition as well as cognitive blockages. The
second carrier (II.6) was a 34-year-old pregnant woman.
She had performed very poorly at school. Her IQ was 86
(borderline). She scored high in anxiety (80) and on the
scale of anxiety-related disorders (76), suggesting the
presence of significant high levels of anxiety and stress
most of the time, with fears and perseverative thoughts of
catastrophe. A generalized anxiety disorder was diagnosed
based on TCI-R. Cognitive problems such as difficulties
in working memory, verbal and semantic fluency, and
organization were detected. The uncle II.2 and the aunt
II.3 (Fig. 2G) did not present the 2p16.3 deletion and
had an average intelligence.
Discussion
The increasing use of the whole genome high-resolution
aCGH technique in the evaluation of affected patients has
identified new CNVs associated with ID, autism, and
schizophrenia.
We have identified in three unrelated patients a 2p16.3
deletion including intron 5 of the NRXN1 gene in the
overlapping region, with a mean length of 520 kb
(Fig. 1). These deletions involve different molecular
regions: the a isoform is affected in cases 1 and 3,
whereas a and b isoforms are affected in case 2. Defects
involving NRXN1-b appear to be rare compared to those
involving only NRXN1-a (Duong et al. 2012; Dabell et al.
2013)Approximately 101 cases of CNVs in 2p16.3 includ-
ing the NRXN1 gene have been described, 95 deletions
Table 3. Summary of proband’s clinical data.
Case 1 Case 2 Case 3
Intellectual disability Mild Mild Mild
Psychiatric disorder Bipolar disorder Non specified psychotic disorder 1
Challenge behavior + + +
Autistic traits  + +
Dysmorphic features
Weight 97th centiles 25th centiles 3rd centiles
Height >97th centiles 3–10th centiles 3rd centiles
OFC +1 SD 1.5 SD 3rd centiles
Long face + + +
Deep set eyes + + +
Hypotelorism + + 
Low set ears + + 
Prominent premaxilla + + +
High palate + + 
Narrow palate +  
Tooth malposition +  
Dorsal kyphosis + + 
Long hands + + 
Long philtrum   +
Family history
Family history of borderline IQ (dysexecutive pattern)  Mother Mother and two aunts
Family history of psychiatric disorder (anxiety)  Mother Mother and two aunts
SD, standard deviation; OFC, occipitofrontal circumference; IQ, intelligence quotient.
1Still young to develop mental illness.
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and 6 duplications, with a mean size of 388.97 kb (Fried-
man et al. 2006; Szatmari et al. 2007; Kirov et al. 2008;
Zahir et al. 2008; Rujescu et al. 2009; Ching et al. 2010;
Magri et al. 2010; Wisniowiecka-Kowalnik et al. 2010;
Duong et al. 2012; Hedges et al. 2012; Schaaf et al. 2012;
Bena et al. 2013). The a isoform is affected in all cases,
whereas the b isoform is additionally affected in only 21
cases.
A recurrent phenotype with ID, language delay, motor
developmental delay, ASD, and hypotonia has been
described in patients affected by the NRXN1 deletion
(Bena et al. 2013). In addition, Schaaf et al. (2012)
reported a larger head size and epilepsy associated to
deletions in the b isoform, but in general dysmorphic
descriptions are scarce and disparate. In this study, the
three patients share some dysmorphic features: long face,
deep set eyes, and prominent premaxilla. The two adult
probands also showed hypotelorism, the most frequent
feature described in patients with NRXN1 deletion (Ching
et al. 2010; Schaaf et al. 2012), low set ears, high palate,
and dorsal kyphosis. All three patients presented dual
diagnosis of mild ID and challenging behavior (child) or
mild ID and mental health disease (adults). However,
they did not share the same psychiatric diagnosis: bipolar
disorder, nonspecified psychotic disorder with atypical
autism and autistic traits in cases 1, 2, and 3, respectively.
It should be noted that case 3 was still a child, and most
psychiatric diseases are diagnosed from adolescence
onwards. The psychiatric diagnosis of the probands is in
agreement with previous observations that NRXN1 hap-
loinsufficiency confers risk of a wide spectrum of psychi-
atric diseases, including ASD, anxiety, depression, bipolar
disorder, and attention deficit hyperactive disorder (Wis-
niowiecka-Kowalnik et al. 2010; Schaaf et al. 2012; Noor
Figure 3. Case 1. (A) Pattern; (B) Rey–Osterriech complex figure
copy; (C) Rey–Osterriech complex figure memory.
Figure 4. Case 2. (A) Pattern and Rey–Osterriech complex figure
copy; (B) Rey–Osterriech complex figure memory.
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et al. 2014). The neuropsychological evaluation high-
lighted a characteristic cognitive pattern of dysexecutive
syndrome shared by the two adults, which includes diffi-
culties in working memory, attention switching, mental
flexibility, and verbal fluency in the absence of aphasia,
amnesia, agnosia, and apraxia. However, the main obsta-
cle to their integration in supported employment pro-
grams was not their cognitive pattern but their
challenging behavioral profile.
The prevalence of the NRXN1 deletion is higher in
patients compared to the control population (Schaaf et al.
2012), but rearrangements in the NRXN1 gene are fre-
quent in the control population (Redon et al. 2006).
Indeed, the largest cohort reported NRXN1 deletions
inherited from a healthy parent in 40% of cases (Bena
et al. 2013). The presence of deletions in control cases
and the inheritance of this variant suggests the possibility
of incomplete penetrance (Duong et al. 2012). However,
no comprehensive psychological or psychiatric evaluation
of carriers has been performed to date.
All participants with a 2p16.3 deletion in our study
with the exception of the probands seemed unaffected at
first. However, a comprehensive evaluation diagnosed var-
ious cognitive, psychiatric, and behavioral disorders.
Although carrier members did not present any dysmor-
phic feature, they showed an IQ between 69 and 91 (bor-
derline to average), as well as behavior and personality
disorders, in particular, impulsivity and anxiety. The high
levels of anxiety are in agreement with the high preva-
lence of anxiety traits found in the mouse model with a
homozygous deletion of the Nrxn1 gene (Grayton et al.
2013). All carriers presented a cognitive profile character-
ized by dysexecutive syndrome with symptoms similar to
the adult probands, in the absence of aphasia, amnesia,
agnosia, and apraxia. The NRXN1 deletion affects cogni-
tive traits in all carriers suggesting that these CNVs could
have variable expressivity instead of incomplete pene-
trance. This hypothesis is in accordance with a recent
study that conducted neuropsychological and psychiatric
examinations. The neuropsychiatric CNVs carriers showed
cognitive abilities between those of normal controls and
ID patients (Stefansson et al. 2014). These data highlight
the need for a neuropsychological and psychiatric evalua-
tion of CNVs carriers in the normal IQ range before
defining the pathogenicity of a genetic variant. The vari-
able spectrum phenotype is an important consideration
when providing genetic counseling.
The variable expressivity in deletion 2p16.2 could also
be caused by additional genomic imbalances such as other
rare CNVs found in some patients (Table 2). Some genes
influencing brain function were: RABG3GAP1, involved
in the regulation of neurotransmitters and exocytosis of
hormones; PDE4D, involved in various signal transduc-
tion pathways such as learning and memory; GFRA1,
related to neuronal differentiation and survival; and
SUF1, a growth factor regulator in early embryonic devel-
opment. The interaction of different CNVs to modulate
phenotypes supports theories such as the digenic/multi-
factorial model for neuropsychiatric diseases or the two-
hit model, in which some aberrations occur in combina-
tion with other genomic CNVs (Girirajan et al. 2010; Liu
et al. 2011). The additional genomic imbalances observed
in our three patients may not be directly responsible for
the dual diagnosis, but its effect in the phenotype should
be considered.
In summary, we have described a common dysmorphic
phenotype in three cases affected by a 2p16.3 deletion in
addition to a common cognitive and psychiatric profile
with different levels of severity among all carriers. The
NRXN1 gene deletion is a risk factor for dual diagnosis
with a variable expressivity.
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